MedTrace Logo

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

NCT01181960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1066

Last updated 2014-02-12

No results posted yet for this study

Summary

The purpose of this study is to build a data repository that can be used to understand pharmaceutical utilization patterns among patients being treated in community behavioral health organizations (CBHOs) for schizophrenia or bipolar I disorder.

Conditions

Interventions

DRUG

Risperidone long acting injectable - New Starts

Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.

DRUG

Risperidone long acting injectable - Continuous Users

Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.

DRUG

Paliperidone Palmitate -New and Continuous Users

Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment

DRUG

Other Antipsychotics - New Starts

Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Scientific Affairs, LLC Clinical Trial · Janssen Scientific Affairs, LLC

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01181960 on ClinicalTrials.gov